Expert Interviews

David Aggen, MD, PhD discusses trends in renal cell carcinoma (RCC) incidence.

Closing out their discussion on mobocertinib data and the EXCLAIM cohort, experts share hope for the future management of the EGFR exon 20 insertion–positive mNSCLC.

A brief review of biomarker testing in metastatic non–small cell lung cancer to identify alterations such as the EGFR exon 20 insertion.

Yelena Y. Janjigian, MD, spoke about which biomarkers were most predictive for treatment of localized gastric cancer.

Shared insight on how real-world experience and data with proteasome inhibitors in multiple myeloma compare to what was seen in clinical trials.

A broad look at the historical use of proteasome inhibitor therapy in patients with multiple myeloma centered on 3 agents: bortezomib, carfilzomib, and ixazomib.

During the Association of Community Cancer Centers 48th Annual Meeting & Cancer Center Business Summit, Candice Roth, MSN, RN, CENP, spoke about electronic pathways embedded in electronic medical records.

Jhalak Dholakia, MD, discusses the promising neoadjuvant combination of of carboplatin and mirvetuximab soravtansine in folate receptor α–positive advanced-stage ovarian, fallopian tube, or primary peritoneal cancer.

An expert in hematology/oncology reviews study data and results from the phase 3 REACH3 trial for steroid-refractory chronic graft-vs-host disease.

Dr Yi-Bin Chen discusses the indications of ibrutinib, ruxolitinib, and belumosudil in steroid-refractory chronic graft-vs-host disease and shares his approach to selecting the optimal therapy for patients.

Catherine Watson, MD, discussed the main results and key takeaway from a trial analyzing streamlined and traditional education practices for patients with ovarian cancer.

Oncologists give their initial impressions about the results of a clinical trial studying doublet combination therapies for advanced renal cell carcinoma.

Robert J. Motzer, MD, presents data examined in the article, “Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.”

Variables that impact decisions to treat HER2-positive breast cancer and brain metastases with radiation therapy and systemic therapy, and recommendations on using memantine following radiation therapy.

Treatment recommendations for patients with HER2-positive metastatic breast cancer, like Erika Rich, upon identification of lesions in the brain.

Dr Liaw discusses ways to measure response to treatment and what recent data regarding PSA kinetics has shown.

Dr Bobby Liaw talks about relationship between treatment duration, dosing and efficacy.

At 2022 ASCO GU, Toni K. Choueiri, MD, explained the data seen in the updated results from the KEYNOTE-564 trial for patients with renal cell carcinoma.

Drs Richter and Fanning discuss next steps and future directions in the management of patients with relapsed/refractory multiple myeloma.

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, spoke about how immunotherapy has influenced treatment for patients with bladder cancer.